Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cyclophosphamide Dose Comparison for GVHD Prophylaxis
NCT05158608Phase 3Unknown
- Sponsor
- National Medical Research Center for Hematology
- Start
- Jan 2022
- Primary completion
- Jan 2024
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of cyclophosphamide in graft-versus-host disease (GVHD), sponsored by National Medical Research Center for Hematology. Status: unknown.
02
Drugs
cyclophosphamide
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT05158608.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05158608.